NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Company Overview - NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel, first-in-class and best-in-class therapies for cancer, including NC410, a LAIR-2 fusion protein, and LNCB74, a novel ADC targeting B7-H4 [2] - The company also has a non-oncology preclinical asset, NC181, a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease [2] Upcoming Events - NextCure will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 [3] Investor Information - For investor inquiries, Timothy Mayer, Ph.D., serves as the Chief Operating Officer and can be contacted at (240) 762-6486 or via email at IR@nextcure.com [2]